Clinical Trials Directory

Trials / Conditions / Refractory Colorectal Carcinoma

Refractory Colorectal Carcinoma

11 registered clinical trials studyying Refractory Colorectal Carcinoma — 1 currently recruiting.

StatusTrialSponsorPhase
RecruitingCPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Pati
NCT05733000
Northwestern UniversityPhase 2
WithdrawnGuadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer
NCT03576963
University of Southern CaliforniaPhase 1 / Phase 2
UnknownFruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer
NCT06221423
Fudan University—
Active Not RecruitingTAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer
NCT04294264
Rutgers, The State University of New JerseyPhase 2
Active Not RecruitingCirculating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorect
NCT03844620
M.D. Anderson Cancer CenterPhase 2
CompletedNivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer
NCT03800602
Emory UniversityPhase 2
TerminatedAutologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Ca
NCT03610490
M.D. Anderson Cancer CenterPhase 2
CompletedM7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instabil
NCT03436563
M.D. Anderson Cancer CenterPhase 1 / Phase 2
CompletedCapecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colo
NCT02873195
Academic and Community Cancer Research UnitedPhase 2
Active Not RecruitingDanvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung C
NCT02983578
M.D. Anderson Cancer CenterPhase 2
Active Not RecruitingM6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Rem
NCT02595931
National Cancer Institute (NCI)Phase 1